高级检索
    刘嘉淇, 梅世琪, 周清. 帕博利珠单抗联合化疗治疗转移性鳞状非小细胞肺癌：KEYNOTE-407的5年更新数据[J]. 循证医学, 2023, 23(4): 197-202. DOI: 10.12019/j.issn.1671-5144.2023.04.002
    引用本文: 刘嘉淇, 梅世琪, 周清. 帕博利珠单抗联合化疗治疗转移性鳞状非小细胞肺癌：KEYNOTE-407的5年更新数据[J]. 循证医学, 2023, 23(4): 197-202. DOI: 10.12019/j.issn.1671-5144.2023.04.002
    shu
    LIU Jia-qi, MEI Shi-qi, ZHOU Qing. Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small-Cell Lung Cancer: 5-Year Update of KEYNOTE-407 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 197-202. DOI: 10.12019/j.issn.1671-5144.2023.04.002
    Citation: LIU Jia-qi, MEI Shi-qi, ZHOU Qing. Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small-Cell Lung Cancer: 5-Year Update of KEYNOTE-407 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 197-202. DOI: 10.12019/j.issn.1671-5144.2023.04.002
    shu

    帕博利珠单抗联合化疗治疗转移性鳞状非小细胞肺癌：KEYNOTE-407的5年更新数据

    Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small-Cell Lung Cancer: 5-Year Update of KEYNOTE-407 Study

      摘要
      • HTML全文
      • 参考文献(9)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回